Marion, William http://orcid.org/0000-0003-3126-8432
Koppe, Tiago
Chen, Chun-Chin
Wang, Dahai
Frenis, Katie http://orcid.org/0000-0003-4103-0882
Fierstein, Sara http://orcid.org/0000-0002-3192-6530
Sensharma, Prerana
Aumais, Olivia
Peters, Michael
Ruiz-Torres, Sonya
Chihanga, Tafadzwa
Boettcher, Steffen
Shimamura, Akiko http://orcid.org/0000-0002-4683-9958
Bauer, Daniel E.
Schlaeger, Thorsten
Wells, Susanne I.
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Starczynowski, Daniel http://orcid.org/0000-0002-5771-7462
da Rocha, Edroaldo Lummertz http://orcid.org/0000-0003-0537-4223
Rowe, R. Grant http://orcid.org/0000-0003-3620-2950
Article History
Received: 19 January 2023
Revised: 25 May 2023
Accepted: 13 June 2023
First Online: 30 June 2023
COMPETING INTERESTS
: BLE has received research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics.